

## Abstract

Modern diagnostic method magnetic resonance imaging (MRI) usually uses contrast agents  $T_1$ -type, which are based on  $Gd^{3+}$  complexes. Due to severe toxicity of free  $Gd^{3+}$ , it is desired to have thermodynamically stable and kinetically inert complexes with fast elimination from the body. This work summarizes information about a novel contrast agent based on ligand  $DO_3A^P$  (1,4,7,10-tetraazacyclododecane-1-methyl(alkyl)phosphinic-4,7,10-triacetic acid) with pendant hydrophobic dibenzylamino group which is able to interact hydrophobically with the macromolecule of serum albumin. The stability of supracomplex is dependent on pH value, *i.e.* on the protonation of the pendant amino group of the complex ( $pK_A = 5.6$ ) and this interaction was confirmed from  $^1H$ -NMRD profile and fluorescent analysis. The compound was tested for its angiographic properties *in vivo* on rat model. Furthermore, other complexes of the ligand with trivalent lanthanides ( $Nd^{3+}$ ,  $Eu^{3+}$ ,  $Tb^{3+}$ ,  $Dy^{3+}$ ,  $Er^{3+}$ ) were characterized by various methods (XRD, luminescence, UV-VIS,  $^1H$ -,  $^{17}O$ - and  $^{31}P$ -NMR). The cleavage of the benzyl groups affords ligand whose  $Ln^{3+}$  complexes possess pH dependent PARACEST effect. These complexes were characterized by XRD, luminescence and  $^1H$ - and  $^{31}P$ -NMR. Moreover, the novel ligands with modified length of pendant arm and with dibenzylamino group were synthesized. The altered value of  $pK_A$  was determined by NMR titration method.

## Keywords

MRI, gadolinium, macrocyclic ligands, macrocyclic complexes, serum albumin